Duration of migraine is a predictor for response to botulinum toxin type A.
Eross EJ; Gladstone JP; Lewis S; Rogers R; Dodick DW; Headache: The Journal of Head & Face Pain, 2005, vol. 45, issue 4, p 308, ISSN 00178748. ISBN 00178748.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef